Objective To study the clinical features of children with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant infection. Methods A retrospective analysis was performed on the medical data of 201 children with coronavirus disease 2019 (COVID-19) who were hospitalized and diagnosed with SARS-CoV-2 Omicron variant infection in Quanzhou First Hospital from March 14 to April 7, 2022. Among the 201 children, there were 34 children with asymptomatic infection and 167 with symptomatic infection. The two groups were compared in terms of clinical features, results of experimental examinations, and outcome. Results Of all the 201 children, 161 (80.1%) had a history of exposure to COVID-19 patients and 132 (65.7%) had a history of COVID-19 vaccination. Among the 167 children with symptomatic infections, 151 had mild COVID-19 and 16 had common COVID-19, with no severe infection or death. Among the 101 children who underwent chest CT examination, 16 had ground glass changes and 20 had nodular or linear opacities. The mean time to nucleic acid clearance was (14±4) days for the 201 children with Omicron variant infection, and the symptomatic infection group had a significantly longer time than the asymptomatic infection group [(15±4) days vs (11±4) days, P<0.05]. The group vaccinated with one or two doses of COVID-19 vaccine had a significantly higher positive rate of IgG than the group without vaccination (P<0.05). The proportions of children with increased blood lymphocyte count in the symptomatic infection group was significantly lower than that in the asymptomatic infection group (P<0.05). Compared with the asymptomatic infection group, the symptomatic infection group had significantly higher proportions of children with increased interleukin-6, increased fibrinogen, and increased D-dimer (P<0.05). Conclusions Most of the children with Omicron variant infection have clinical symptoms, which are generally mild. The children with symptomatic infection are often accompanied by decreased or normal blood lymphocyte count and increased levels of interleukin-6, fibrinogen, and D-dimer, with a relatively long time to nucleic acid clearance. Some of them had ground glass changes on chest CT.
Key words
Coronavirus disease 2019 /
Omicron variant /
Clinical feature /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
1 Ai J, Zhang H, Zhang Y, et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost[J]. Emerg Microbes Infect, 2022, 11(1): 337-343. PMID: 34935594. PMCID: PMC8788341. DOI: 10.1080/22221751.2021.2022440.
2 焦富勇, 马蕾. 加强儿童奥密克戎感染的防治[J]. 中国当代儿科杂志, 2022, 24(4): 345-349. PMID: 35527405. PMCID: PMC9044981. DOI: 10.7499/j.issn.1008-8830.2201001.
3 中华人民共和国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第九版)[J]. 中华临床感染病杂志, 2022, 15(2): 81-89. DOI :10.3760/cma.j.issn.1674-2397.2022.02.001.
4 中华人民共和国国家卫生健康委员会. 儿童血细胞分析参考区间:WS/T 779-2021[S/OL]. ( 2021-04-19) [2022-06-20]. http://www.nhc.gov.cn/wjw/s9492/202105/19e3455a5dfe47e7a84756dd3968e475/files/f206930de56a400b9a8a33e5e59f6c05.pdf.
5 刘晓芳, 陈美平, 周志国, 等. 17例新型冠状病毒Omicron变异株境外输入感染者的流行病学特征[J]. 中南大学学报(医学版), 2022, 47(3): 344-351. PMID: 35545327. DOI: 10.11817/j.issn.1672-7347.2022.220040.
6 Tagarro A, Coya ON, Pérez-Villena A, et al. Features of COVID-19 in children during the Omicron wave compared with previous waves in Madrid, Spain[J]. Pediatr Infect Dis J, 2022, 41(5): e249-e251. PMID: 35333818. PMCID: PMC8997014. DOI: 10.1097/INF.0000000000003482.
7 Smith DJ, Hakim AJ, Leung GM, et al. COVID-19 mortality and vaccine coverage: Hong Kong Special Administrative Region, China, January 6, 2022 - March 21, 2022[J]. MMWR Morb Mortal Wkly Rep, 2022, 71(15): 545-548. PMID: 35421076. PMCID: PMC9020860. DOI: 10.15585/mmwr.mm7115e1.
8 Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa: a data linkage study[J]. Lancet, 2022, 399(10323): 437-446. PMID: 35065011. PMCID: PMC8769664. DOI: 10.1016/S0140-6736(22)00017-4.
9 刘洁, 罗万军, 邓志宏, 等. 91例儿童新型冠状病毒肺炎确诊病例临床及流行病学特征[J]. 中华医院感染学杂志, 2020, 30(11): 1625-1629. DOI: 10.11816/cn.ni.2020-200550.
10 Haghi Ashtiani MT, Sadeghi Rad P, Asnaashari K, et al. Role of serology tests in COVID-19 non-hospitalized patients: a cross-sectional study[J]. PLoS One, 2022, 17(4): e0266923. PMID: 35421183. PMCID: PMC9009643. DOI: 10.1371/journal.pone.0266923.
11 Sughayer MA, Souan L, Abu Alhowr MM, et al. Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: Implications for vaccine strategies[J]. Vaccine, 2022, 40(20): 2841-2847. PMID: 35397946. PMCID: PMC8971065. DOI: 10.1016/j.vaccine.2022.03.069.
12 张平平, 郭艳婷, 初玉芹, 等. 110例儿童奥密克戎变异株感染恢复期血清IgG抗体变化[J]. 中国当代儿科杂志, 2022, 24(7): 736-741. PMID: 35894186. PMCID: PMC9336630. DOI: 10.7499/j.issn.1008-8830.2204074.
13 Jara A, Undurraga EA, Zubizarreta JR, et al. Effectiveness of CoronaVac in children 3-5 years of age during the SARS-CoV-2 Omicron outbreak in Chile[J]. Nat Med, 2022, 28(7): 1377-1380. PMID: 35605637. PMCID: PMC9307483. DOI: 10.1038/s41591-022-01874-4.
14 Fowlkes AL, Yoon SK, Lutrick K, et al. Effectiveness of 2-dose BNT162b2 (pfizer BioNTech) mRNA vaccine in preventing SARS-CoV-2 infection among children aged 5-11 years and adolescents aged 12-15 years: PROTECT cohort, July 2021-February 2022[J]. MMWR Morb Mortal Wkly Rep, 2022, 71(11): 422-428. PMID: 35298453. PMCID: PMC8942308. DOI: 10.15585/mmwr.mm7111e1.
15 吕媛, 舒桂华, 侯玮玮, 等. 扬州地区新型冠状病毒delta变异株感染54例儿童临床特点分析[J]. 临床儿科杂志, 2022, 40(4): 252-257. DOI: 10.12372/jcp.2022.21e1264.
16 Boehme AK, Doyle K, Thakur KT, et al. Disorders of consciousness in hospitalized patients with COVID-19: the role of the systemic inflammatory response syndrome[J]. Neurocrit Care, 2022, 36(1): 89-96. PMID: 34184176. PMCID: PMC8238027. DOI: 10.1007/s12028-021-01256-7.
17 Mukund K, Mathee K, Subramaniam S. Plasmin cascade mediates thrombotic events in SARS-CoV-2 infection via complement and platelet-activating systems[J]. IEEE Open J Eng Med Biol, 2020, 1: 220-227. PMID: 34786557. PMCID: PMC8527892. DOI: 10.1109/OJEMB.2020.3014798.
18 Zhang S, Liu L, Yang B, et al. Clinical characteristics of 134 convalescent patients with COVID-19 in Guizhou, China[J]. Respir Res, 2020, 21(1): 314. PMID: 33243228. PMCID: PMC7689638. DOI: 10.1186/s12931-020-01580-0.
19 Zhang Q, Xu Q, Chen YY, et al. Clinical characteristics of 41 patients with pneumonia due to 2019 novel coronavirus disease (COVID-19) in Jilin, China[J]. BMC Infect Dis, 2020, 20(1): 961. PMID: 33334317. PMCID: PMC7745171. DOI: 10.1186/s12879-020-05677-1.
20 Wang F, Qu M, Zhou X, et al. The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China[J]. J Transl Med, 2020, 18(1): 270. PMID: 32620125. PMCID: PMC7332535. DOI: 10.1186/s12967-020-02423-8.
PDF(675 KB)
